1096485-24-3
![1096485-24-3 结构式](/CAS/20200611/GIF/1096485-24-3.gif)
基本信息
Neuronostatin trifluoroacetate salt
Neuronostatin-13 trifluoroacetate salt
Leu-Arg-Gln-Phe-Leu-Gln-Lys-Ser-Leu-Ala-Ala-Ala-Ala-NH2 trifluoroacetate salt
L-Alaninamide, L-leucyl-L-arginyl-L-glutaminyl-L-phenylalanyl-L-leucyl-L-glutaminyl-L-lysyl-L-seryl-L-leucyl-L-alanyl-L-alanyl-L-alanyl-
L-Leucyl-L-arginyl-L-glutaminyl-L-phenylalanyl-L-leucyl-L-glutaminyl-L-lysyl-L-seryl-L-leucyl-L-alanyl-L-alanyl-L-alanyl-L-alaninamide trifluoroacetate salt
报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
2024/08/19 | HY-P1373 | Neuronostatin-13 trifluoroacetate salt Neuronostatin-13 (human) | 1096485-24-3 | 1mg | 2200元 |
2024/08/19 | HY-P1373 | Neuronostatin-13 trifluoroacetate salt Neuronostatin-13 (human) | 1096485-24-3 | 5mg | 6600元 |
常见问题列表
Neuronostatin-13 human is a 13-amino acid peptide hormone encoded by the somatostatin gene and plays an important role in the regulation of hormonal and cardiac function. Treatment with Neuronostatin-13 human (1,000 nM) enhances low-glucose-induced glucagon release compare with islets treated with control medium alone. Treatment with Neuronostatin-13 human for 1 h leads to a significant increase in the accumulation of glucagon mRNA compare with vehicle-treated control cells. In αTC1-9 α-cells, treatment with 100 nM Neuronostatin-13 human leads to an increase in phosphorylated PKA at 30 and 40 min.
Infusion with Neuronostatin-13 human delays glucose clearance in the rat model, such that blood glucose levels in Neuronostatin-13 human-treated animals are significantly higher at 1 and 10 min following intra-arterial injection of a glucose bolus. Chocardiographic measurement reveals a remarkable drop in heart rate after 3-, 6- and 12-hr of Neuronostatin-13 human challenge. In addition, Neuronostatin-13 human treatment significantly decreases left ventricular end-systolic diameter (LVESD) and fractional shortening without affecting left ventricular end-diastolic diameter (LVEDD) between 6 and 12 hrs following Neuronostatin-13 human challenge, the effect of which returns to basal level 18-hr after Neuronostatin-13 human treatment.